318 related articles for article (PubMed ID: 34004039)
1. Chiral separation in the class of proton pump inhibitors by chromatographic and electromigration techniques: An overview.
Papp LA; Hancu G; Kelemen H; Tóth G
Electrophoresis; 2021 Sep; 42(17-18):1761-1789. PubMed ID: 34004039
[TBL] [Abstract][Full Text] [Related]
2. Stereoselective disposition of proton pump inhibitors.
Andersson T; Weidolf L
Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
[TBL] [Abstract][Full Text] [Related]
3. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
4. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Kromer W
Scand J Gastroenterol Suppl; 2001; (234):3-9. PubMed ID: 11768559
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Abed MN; Alassaf FA; Jasim MHM; Alfahad M; Qazzaz ME
Pharmacology; 2020; 105(11-12):645-651. PubMed ID: 32289807
[TBL] [Abstract][Full Text] [Related]
7. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
8. Determination of Proton Pump Inhibitors by Spectrophotometric, Chromatographic and by Hyphenated Techniques: A Review.
Joshi AA; Nerkar PP
Crit Rev Anal Chem; 2021; 51(6):527-548. PubMed ID: 32312104
[TBL] [Abstract][Full Text] [Related]
9. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Li MJ; Li Q; Sun M; Liu LQ
Medicine (Baltimore); 2017 Sep; 96(39):e8120. PubMed ID: 28953640
[TBL] [Abstract][Full Text] [Related]
12. Qualimetric analysis of proton pump inhibitors in Ukraine.
Makarenko OV; Karimova MM; Masheiko AM; Onul NM
Wiad Lek; 2019; 72(9 cz 2):1769-1773. PubMed ID: 31622264
[TBL] [Abstract][Full Text] [Related]
13. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
14. [All proton pump inhibitors are equally efficacious in standard dosages].
Hellström PM; Vitols S
Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
[TBL] [Abstract][Full Text] [Related]
15. An overview of proton pump inhibitors.
Der G
Gastroenterol Nurs; 2003; 26(5):182-90. PubMed ID: 14603076
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in chirally pure proton pump inhibitors.
Pai V; Pai N
J Indian Med Assoc; 2007 Aug; 105(8):469-70, 472, 474. PubMed ID: 18236913
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use.
Chen F; He X; Fang B; Wang S
Drug Des Devel Ther; 2020; 14():5689-5698. PubMed ID: 33380789
[TBL] [Abstract][Full Text] [Related]
18. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Edwards SJ; Lind T; Lundell L
Aliment Pharmacol Ther; 2006 Sep; 24(5):743-50. PubMed ID: 16918878
[TBL] [Abstract][Full Text] [Related]
19. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
20. Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Lespessailles E; Toumi H
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
